Log in to save to my catalogue

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐I...

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐I...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b5ce3ba8cf5044599fe4be3169162079

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design

About this item

Full title

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design

Publisher

England: John Wiley & Sons, Inc

Journal title

ESC Heart Failure, 2020-04, Vol.7 (2), p.747-756

Language

English

Formats

Publication information

Publisher

England: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Aims
In univentricular hearts, selective lung vasodilators such as phosphodiesterase type 5 (PDE5) inhibitors would decrease pulmonary resistance and improve exercise tolerance. However, the level of evidence for the use of PDE5 inhibitors in patients with a single ventricle (SV) remains limited. We present the SV‐INHIBITION study rationale, des...

Alternative Titles

Full title

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_b5ce3ba8cf5044599fe4be3169162079

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b5ce3ba8cf5044599fe4be3169162079

Other Identifiers

ISSN

2055-5822

E-ISSN

2055-5822

DOI

10.1002/ehf2.12630

How to access this item